Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Comparing the effectiveness of combined therapy of bortezomib, melphalan, and prednisone with versus without daratumumab in patients with multiple myeloma ineligible for a transplant

Comparing the effectiveness of combined therapy of bortezomib, melphalan, and prednisone with versus without daratumumab in patients with multiple myeloma ineligible for a transplant

Posted by on Sep 17, 2023 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated the effectiveness of combined therapy of bortezomib (Velcade), melphalan (Alkeran), and prednisone (Deltasone) with (D-VMP) versus without (VMP) daratumumab (Darzalex) in transplant-ineligible patients newly diagnosed with multiple myeloma (MM). The study concluded that D-VMP was more effective than using...

Read More

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Posted by on Aug 27, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...

Read More

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Posted by on Jul 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that over the long term adding isatuximab to the Kd regimen was effective with manageable side...

Read More

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Posted by on Apr 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) combination as induction therapy for patients with newly diagnosed transplantation-eligible multiple myeloma (MM). The data showed that the addition of isatuximab to lenalidomide,...

Read More

Evaluating the effectiveness of lenalidomide-containing triplet regimens in patients with first relapsed multiple myeloma.

Evaluating the effectiveness of lenalidomide-containing triplet regimens in patients with first relapsed multiple myeloma.

Posted by on Feb 28, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of lenalidomide (Revlimid)-containing regimens in patients with first relapsed multiple myeloma (MM). The data showed that daratumumab (Darzalex) combined with lenalidomide and dexamethasone (Rd) regimen significantly increased the survival without cancer worsening with fewer serious side effects...

Read More

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Posted by on Feb 5, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of replacing lenalidomide (Revlimid) with pomalidomide (Pomalyst) for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) who were unresponsive to a lenalidomide-containing combination regimen. The data showed that pomalidomide was a safe and effective...

Read More

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Posted by on Dec 4, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma (MM) ineligible for a transplant. The data showed that first-line treatment should be based on daratumumab (Darzalex)-based regimens or the VRd regimen [bortezomib (V; Velcade), lenalidomide...

Read More

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...

Read More

Evaluating the long-term effectiveness and safety of injections under the skin of daratumumab versus intravenous infusions for patients with relapsed or refractory multiple myeloma.

Evaluating the long-term effectiveness and safety of injections under the skin of daratumumab versus intravenous infusions for patients with relapsed or refractory multiple myeloma.

Posted by on Sep 20, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study reported the final effectiveness and safety of subcutaneous (SC) injections versus intravenous (IV) infusions of daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma (MM). The data showed that daratumumab SC injections were as effective and caused fewer side effects than IV infusions over the long term...

Read More

Evaluating the effectiveness and safety outcomes of administering radiotherapy at the same time with DCEP salvage chemotherapy in patients with multiple myeloma.

Evaluating the effectiveness and safety outcomes of administering radiotherapy at the same time with DCEP salvage chemotherapy in patients with multiple myeloma.

Posted by on Sep 17, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of administering radiotherapy (RT) at the same time as DCEP salvage chemotherapy in patients with unresponsive multiple myeloma (MM). This study concluded that RT administered at the same time with DCEP salvage chemotherapy was effective and well-tolerated by most of the...

Read More

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Posted by on Sep 11, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-containing regimens in patients with multiple myeloma (MM) unresponsive to lenalidomide (Revlimid) maintenance therapy. The data showed that daratumumab-containing therapies are effective regimens in these patients. Some background Multiple myeloma (MM) is a type...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More